Novel treatment options for refractory germ cell tumors

Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of pati...

Full description

Saved in:
Bibliographic Details
Published in:Update on cancer therapeutics 2008-12, Vol.3 (2), p.89-96
Main Authors: Kondagunta, G. Varuni, Sonpavde, Guru, Galsky, Matthew D., Fleming, Mark T., Hutson, Thomas E., Sternberg, Cora N.
Format: Article
Language:English
Subjects:
Germ cell tumors
Novel agents
Salvage therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.
ISSN:1872-115X
1872-115X
DOI:10.1016/j.uct.2008.10.001